HalozymeHALO
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 350
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
185% more call options, than puts
Call options by funds: $36.9M | Put options by funds: $12.9M
13% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 80
0% more funds holding
Funds holding: 499 [Q3] → 500 (+1) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 178
1.3% less ownership
Funds ownership: 97.95% [Q3] → 96.65% (-1.3%) [Q4]
17% less capital invested
Capital invested by funds: $7.1B [Q3] → $5.86B (-$1.24B) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Leerink Partners | 6%downside $47 | Underperform Downgraded | 13 May 2025 |
Wells Fargo Mohit Bansal 30% 1-year accuracy 8 / 27 met price target | 29%upside $65 | Equal-Weight Maintained | 7 May 2025 |
HC Wainwright & Co. Mitchell Kapoor 34% 1-year accuracy 60 / 174 met price target | 43%upside $72 | Buy Reiterated | 25 Apr 2025 |
JP Morgan Jessica Fye 49% 1-year accuracy 20 / 41 met price target | 15%upside $58 | Neutral Maintained | 21 Apr 2025 |
Benchmark Robert Wasserman 33% 1-year accuracy 13 / 40 met price target | 49%upside $75 | Buy Reiterated | 20 Feb 2025 |
Financial journalist opinion
Based on 19 articles about HALO published over the past 30 days
